Search research articles
Contact Us
Filters
Showing results (61-70 of 173) with videos related to
Page
of 18
Sort By:
Cytokine
|
December 1, 2000
Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF
K Hübel, G Mansmann, H Schäfer, et al.
Applied and Environmental Microbiology
|
April 1, 2000
Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions
S Barth, M Huhn, B Matthey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 20, 2010
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis
M Scholz, A Engert, J Franklin, et al.
Clinical and Experimental Immunology
|
April 17, 2004
A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin
D Castelletti, G Fracasso, S Righetti, et al.
Medizinische Klinik (Munich, Germany : 1983)
|
October 15, 1992
[New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?]
A Engert, C Gottstein, U Winkler, et al.
Cancer Research
|
November 1, 1990
Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody
U Sahin, F Hartmann, P Senter, et al.
Leukemia & Lymphoma
|
August 3, 2002
T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors
M Reiser, A Josting, M Soltani, et al.
The Cochrane Database of Systematic Reviews
|
July 22, 2004
Erythropoietin for patients with malignant disease
J Bohlius, S Langensiepen, G Schwarzer, et al.
Leukemia
|
January 22, 1998
A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma
K Hübel, H Tesch, B Kröger, et al.
Leukemia & Lymphoma
|
May 1, 1994
Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins
A Engert, C Gottstein, U Winkler, et al.
Page
of 18
Search research articles
Search
Showing results (61-70 of 173) with videos related to
Sort By:
Page
of 18
Cytokine
|
December 1, 2000
Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF
K Hübel, G Mansmann, H Schäfer, et al.
Applied and Environmental Microbiology
|
April 1, 2000
Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions
S Barth, M Huhn, B Matthey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 20, 2010
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis
M Scholz, A Engert, J Franklin, et al.
Clinical and Experimental Immunology
|
April 17, 2004
A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin
D Castelletti, G Fracasso, S Righetti, et al.
Medizinische Klinik (Munich, Germany : 1983)
|
October 15, 1992
[New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?]
A Engert, C Gottstein, U Winkler, et al.
Cancer Research
|
November 1, 1990
Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody
U Sahin, F Hartmann, P Senter, et al.
Leukemia & Lymphoma
|
August 3, 2002
T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors
M Reiser, A Josting, M Soltani, et al.
The Cochrane Database of Systematic Reviews
|
July 22, 2004
Erythropoietin for patients with malignant disease
J Bohlius, S Langensiepen, G Schwarzer, et al.
Leukemia
|
January 22, 1998
A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma
K Hübel, H Tesch, B Kröger, et al.
Leukemia & Lymphoma
|
May 1, 1994
Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins
A Engert, C Gottstein, U Winkler, et al.
Page
of 18